A Study of Tarlatamab and AB248 for Extensive Stage Small Cell Lung Cancer
This study is testing two drugs, tarlatamab and AB248, in combination for people with extensive stage small cell lung cancer (ES-SCLC) that has progressed after at least one previous treatment. Researchers want to understand how safe this combination is and what dose works best. Tarlatamab and AB248 are given through an IV. This study is looking for people aged 18 to 90 years old. The main goals are to see how many participants experience side effects and to find the best dose of the drugs. The study is currently recruiting about 380 participants.
- Study design
- This interventional study plans to enroll 380 participants. It is testing the safety and tolerability of two drugs in combination.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will track treatment-emergent adverse events (side effects) for up to 2.5 years. Dose-limiting toxicities will be measured for up to 35 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
At a glance
Conditions
Where it's being run
19 sites across 14 statesStudy leadership
- MD · STUDY_DIRECTOR · Amgen
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of Participants with Treatment-emergent Adverse Events (TEAEs)Up to 2.5 years
Clinically significant changes in vital signs and clinical laboratory tests will be reported as adverse events.
- Dose Exploration: Number of Participants with Dose-limiting Toxicities (DLTs)Up to 35 days